ACR Convergence 2022

November 10-14, 2022. Philadelphia, PA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1811

Urate Lowering Therapy Initiation in Hospitalized Patients with Acute Gout Flares
Abstract Number: 1812

Impact of Misclassification on the US Prevalence of Gout: Bayesian Sensitivity Analysis of the National Health & Nutrition Examination Survey (NHANES)
Abstract Number: 1813

Patient-Reported Outcomes in CPPD Compared to Gout and Osteoarthritis
Abstract Number: 1814

Pegloticase for Uncontrolled Gout in Patients with History of Kidney Transplant: Pharmacokinetics and Immunogenicity in the PROTECT Clinical Trial
Abstract Number: 1815

Consistent Colchicine Use Is Associated with Decreased Major Adverse Cardiovascular Events in Patients with Gout and Established Cardiovascular Disease
Abstract Number: 1816

Assessing Urate Deposition and Inflammation in the Vasculature of Gout Patients Using Dual Energy Computed Tomography and Positron Emission Tomography Pre and Post Pegloticase- a Pilot Study
Abstract Number: 1817

Acute Coronary Syndrome in Calcium Pyrophosphate Deposition Disease Patients: A Cross-sectional Study from the National Inpatient Sample
Abstract Number: 1818

Hepatic Steatosis and Fibrosis in Patients with Gout Detected by Elastography
Abstract Number: 1819

Calcium Pyrophosphate Deposition Disease Is Associated with an Increased Prevalence of Nephrolithiasis
Abstract Number: 1820

Targeted Plasma Lipidomics Distinguishes Patients with Gout and Hyperuricemia from Controls
Abstract Number: 1821

Colchicine and Other Gout Medications and the Risk of COVID-19 Infection, Hospitalization, and Subsequent Outcomes in People with Gout
Abstract Number: 1822

A Double-Blind, Placebo-Controlled, Ascending Dose Phase 2a Study of ABP-671, a Novel, Potent and Selective URAT1 Inhibitor, in Patients with Gout or Hyperuricemia
Abstract Number: 1823

Unsupervised Cluster Analysis of Clinical and Ultrasound Features Reveals Unique Gout Subtypes: Results from the Egyptian College of Rheumatology (ECR)
Abstract Number: 1824

eGFR Changes in Uncontrolled Gout Patients Undergoing Pegloticase + Methotrexate Co-therapy
Abstract Number: 1825

Vascular Calcifications Adjacent to the Involved Joint of Patients Diagnosed with Calcium Pyrophosphate Crystal Arthritis – a Retrospective Observational Study

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].